Connection

Andrew Kraft to Male

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Male.
Andrew Kraft
Connection Strength
0.568
Male
  1. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
    View in: PubMed
    Score: 0.043
  2. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
    View in: PubMed
    Score: 0.040
  3. Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chem Biol. 2019 08 15; 26(8):1110-1121.e4.
    View in: PubMed
    Score: 0.036
  4. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther. 2018 12; 17(12):2710-2721.
    View in: PubMed
    Score: 0.034
  5. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017 07 18; 5(1):58.
    View in: PubMed
    Score: 0.032
  6. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47.
    View in: PubMed
    Score: 0.029
  7. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65.
    View in: PubMed
    Score: 0.029
  8. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015 Jan; 27(1):135-46.
    View in: PubMed
    Score: 0.026
  9. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11.
    View in: PubMed
    Score: 0.024
  10. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303.
    View in: PubMed
    Score: 0.021
  11. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
    View in: PubMed
    Score: 0.021
  12. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37.
    View in: PubMed
    Score: 0.020
  13. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41.
    View in: PubMed
    Score: 0.020
  14. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
    View in: PubMed
    Score: 0.018
  15. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100.
    View in: PubMed
    Score: 0.017
  16. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
    View in: PubMed
    Score: 0.014
  17. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
    View in: PubMed
    Score: 0.013
  18. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001 Apr 06; 276(14):10767-74.
    View in: PubMed
    Score: 0.010
  19. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990.
    View in: PubMed
    Score: 0.010
  20. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
    View in: PubMed
    Score: 0.009
  21. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510.
    View in: PubMed
    Score: 0.009
  22. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
    View in: PubMed
    Score: 0.009
  23. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res. 1998 Feb 15; 58(4):834-9.
    View in: PubMed
    Score: 0.008
  24. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate. 1998 Feb 15; 34(3):175-81.
    View in: PubMed
    Score: 0.008
  25. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
    View in: PubMed
    Score: 0.006
  26. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.006
  27. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
    View in: PubMed
    Score: 0.006
  28. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. 2013 Jan 29; 6:12.
    View in: PubMed
    Score: 0.006
  29. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81.
    View in: PubMed
    Score: 0.006
  30. Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8.
    View in: PubMed
    Score: 0.005
  31. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
    View in: PubMed
    Score: 0.005
  32. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
    View in: PubMed
    Score: 0.004
  33. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
    View in: PubMed
    Score: 0.004
  34. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007 Jul; 6(7):1015-7.
    View in: PubMed
    Score: 0.004
  35. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
    View in: PubMed
    Score: 0.003
  36. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84.
    View in: PubMed
    Score: 0.003
  37. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8.
    View in: PubMed
    Score: 0.002
  38. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
    View in: PubMed
    Score: 0.002
  39. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999 Feb; 6(2):175-82.
    View in: PubMed
    Score: 0.002
  40. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem. 1986 Dec; 24(12):1009-16.
    View in: PubMed
    Score: 0.001
  41. [Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.